ANXA2R

Across TCGA pan-cancer cohorts, ANXA2R Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANXA2R data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ANXA2R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA2R expression acts as an unfavorable survival marker.

HNSC, STAD, and SKCM are the cancer types where ANXA2R Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.186	0.769	<.001	48	view →
STAD	OS	Median	All	0.096	0.688	<.001	24	view →
SKCM	OS	Median	All	0.245	0.783	.007	21	view →
PRAD	DFS	Median	All	0.187	0.775	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANXA2R–HNSC (OS)

Open the HNSC breakdown →